Compare MAC & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAC | AXSM |
|---|---|---|
| Founded | 1964 | 2012 |
| Country | United States | United States |
| Employees | 2845 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 7.5B |
| IPO Year | 1994 | 2015 |
| Metric | MAC | AXSM |
|---|---|---|
| Price | $24.06 | $135.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 22 |
| Target Price | $26.87 | ★ $264.62 |
| AVG Volume (30 Days) | ★ 2.7M | 1.0M |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | 11.36 | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,013,983,000.00 | N/A |
| Revenue This Year | N/A | $49.25 |
| Revenue Next Year | $8.59 | $52.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.43 | N/A |
| 52 Week Low | $16.03 | $123.00 |
| 52 Week High | $26.68 | $260.19 |
| Indicator | MAC | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 46.97 | 36.03 |
| Support Level | $23.16 | $123.00 |
| Resistance Level | $25.96 | $225.16 |
| Average True Range (ATR) | 0.59 | 7.85 |
| MACD | -0.09 | 1.71 |
| Stochastic Oscillator | 9.00 | 42.78 |
Macerich invests in premium mall assets. The company owns 28 regional malls in its consolidated portfolio and nine regional malls in its unconsolidated portfolio along with a power center and six other real estate assets. The company's total portfolio has 39.9 million square feet of gross leasable area and averaged $199 in sales per square foot over the 12 months ended in June 2026.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.